{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:12:22Z","timestamp":1781727142742,"version":"3.54.5"},"reference-count":43,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,5]]},"abstract":"\n Aim<\/jats:title>\n The phase 4 RESOLUTION trial showed that, in comparison with placebo, adding eptinezumab\u2014an anti-calcitonin gene-related peptide monoclonal antibody\u2014to a brief educational intervention (BEI) reduced the monthly frequency of migraine, headache, and acute medication use in participants with chronic migraine (CM) and medication-overuse headache (MOH). Herein, we report data from multiple patient-reported outcomes (PROs) evaluating treatment impact on disease burden and health-related productivity and quality of life in the RESOLUTION trial.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n RESOLUTION was a multi-national (conducted at 76 sites across 11 countries), double-blind, randomized, placebo-controlled trial. The trial comprised a 4-week screening period; a 12-week, double-blind, placebo-controlled period; a 12-week, open-label, extension period; and an 8-week, safety follow-up period, with results of the placebo-controlled period presented in this paper. Adults diagnosed with CM and MOH received a BEI and were randomized 1:1 to intravenous infusion with either eptinezumab 100\u2005mg or placebo. Several PROs were assessed at baseline, Week 4, and Week 12, including the six-item Headache Impact Test (HIT-6), modified Migraine Disability Assessment (mMIDAS), Migraine-specific Work Productivity and Activity Impairment questionnaire (WPAI:M), Patient Global Impression of Change (PGIC; assessed only at follow-up), patient-identified most bothersome symptom (PI-MBS; assessed only at follow-up), Migraine-Specific Quality-of-Life questionnaire version 2.1 (MSQ v2.1), EQ-5D-5L visual analogue scale, and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; assessed only at follow-up).\n Post hoc<\/jats:italic>\n analyses included responder rates for HIT-6 (i.e., participants with \u22655-point reduction from baseline), as well as for PGIC and PI-MBS (i.e., participants who reported \u201cmuch improved\u201d or \u201cvery much improved\u201d).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 608 participants randomized, the full-analysis set included 302 participants in the eptinezumab arm and 300 in the placebo arm. Eptinezumab with BEI was associated with more favorable PRO scores compared to placebo with BEI, starting at Week 4 (\n p<\/jats:italic>\n \u2009<\u20090.05 for all comparisons) and up to Week 12 (\n p<\/jats:italic>\n \u2009<\u20090.01 for all comparisons except WPAI:M absenteeism). Responder rates for HIT-6, PGIC, and PI-MBS also favored eptinezumab versus placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In participants with CM and MOH who also received patient education, eptinezumab treatment resulted in greater reductions in headache impact and migraine disability than placebo, with greater improvements in productivity, quality of life, overall disease status, and treatment satisfaction starting from Week 4 and sustained to Week 12. Eptinezumab in combination with patient education is an effective treatment for reducing disease burden and improving overall quality of life in people with CM and MOH.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n ClinicalTrials.gov Identifier: NCT05452239 (\n https:\/\/clinicaltrials.gov\/study\/NCT05452239<\/jats:ext-link>\n ); EudraCT Number: 2021-003049-40 (\n https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2021-003049-40<\/jats:ext-link>\n )\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/03331024261449814","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:18:52Z","timestamp":1778937532000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-6638","authenticated-orcid":false,"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"The New England Institute for Neurology and Headache, Stamford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6262-2986","authenticated-orcid":false,"given":"Henrik W.","family":"Schytz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Rigshospitalet \u2013 Glostrup, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-5887","authenticated-orcid":false,"given":"Rigmor H.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Rigshospitalet \u2013 Glostrup, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-9876","authenticated-orcid":false,"given":"Christofer","family":"Lundqvist","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Health Services Research, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3140-6882","authenticated-orcid":false,"given":"Gisela M.","family":"Terwindt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[{"name":"University of Pavia"},{"name":"IRCCS C. Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-9336","authenticated-orcid":false,"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Campus Bio-Medico"},{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-9234","authenticated-orcid":false,"given":"Michel","family":"Lant\u00e9ri-Minet","sequence":"additional","affiliation":[{"name":"Pain Department and FHU InovPain, Centre Hospitalier Universitaire de Nice, Nice, France"},{"name":"Auvergne University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-4914","authenticated-orcid":false,"given":"Andrew","family":"Blumenfeld","sequence":"additional","affiliation":[{"name":"The Los Angeles Headache Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2840-9505","authenticated-orcid":false,"given":"Mette Krog","family":"Josiassen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5243-2102","authenticated-orcid":false,"given":"Gary","family":"Jansson","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-3012","authenticated-orcid":false,"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2449-807X","authenticated-orcid":false,"given":"Aur\u00e9lia","family":"Mittoux","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-005-0252-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231174855"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1114654"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11880-2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30146-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20100"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1194134"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.124"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14056"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1179"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-01982-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-823357-3.00026-4"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15256"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03094.x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03157.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308548"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01542.x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-10"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.264671"},{"key":"e_1_3_3_27_2","unstructured":"VYEPTI\u00ae (eptinezumab-jjmr) injection for intravenous use. Prescribing information. Lundbeck Seattle BioPharmaceuticals Inc.; 2025. Accessed 13 March 2026."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14434"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14036"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214863"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_3_3_34_2","volume-title":"The HIT-6\u2122: A user\u2019s guide","author":"Bayliss MS","year":"2002","unstructured":"Bayliss MS, Batenhorst AS. The HIT-6\u2122: A user\u2019s guide. Lincoln, RI: QualityMetric Incorporated, 2002."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmpt.2003.11.003"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00066.x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3043"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01144-z"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261449814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261449814","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261449814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:17:30Z","timestamp":1779110250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261449814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/03331024261449814"],"URL":"https:\/\/doi.org\/10.1177\/03331024261449814","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"03331024261449814"}}